Safety and Efficacy Study of BAFF-R CAR-T Cells in Adult Subjects With CD19-Negative Relapsed or Refractory B-Cell Lymphoma

This study is testing a CAR-T cell therapy targeting a protein called BAFF-R for adults with a rare and hard-to-treat form of B-cell lymphoma that lacks the CD19 protein — meaning standard CD19-targeting CAR-T therapies would not work for these patients. **You may be eligible if...** - You are 18 or older - You have relapsed or refractory B-cell lymphoma that is confirmed to be CD19-negative - Your tumor tests positive for the BAFF-R protein - Your cancer failed to respond to or came back after at least two lines of prior treatment - Your expected survival is at least 3 months **You may NOT be eligible if...** - Your lymphoma is CD19-positive (a different CAR-T therapy may be more appropriate) - Your tumor does not express the BAFF-R protein - Your organ function is too poor to tolerate CAR-T therapy - You have active central nervous system lymphoma - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.